Renal Cell Carcinoma Clinical Trials

48 studies are recruiting for renal cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

   A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05048212 on ClinicalTrials.gov

2. Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

   Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participant…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   UCSF Medical Center at Mission Bay ( Site 5008), San Francisco, California

   Locations

   32 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07049926 on ClinicalTrials.gov

3. Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

   This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT05319015 on ClinicalTrials.gov

4. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

5. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

6. Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

   This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Emory University Hospital Midtown, Atlanta, Georgia

   Locations

   13 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04981509 on ClinicalTrials.gov

7. A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

   The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05837767 on ClinicalTrials.gov

8. Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

   This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   2 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT05830058 on ClinicalTrials.gov

9. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   10 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

10. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage

    Not phased

    Ages

    18 to 130

    Site

    Research Site, Birmingham, Alabama

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

11. Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

    We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant di…

    Stage

    Not phased

    Ages

    2 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT00001238 on ClinicalTrials.gov

12. A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

    The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in thi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Stephanie Berg

    See if you can join NCT07123090 on ClinicalTrials.gov

13. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

14. Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

    This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    8 in total

    Run by

    Deciphera Pharmaceuticals, LLC

    See if you can join NCT06966024 on ClinicalTrials.gov

15. Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

    This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT05733715 on ClinicalTrials.gov

16. A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

    This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    11 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07195682 on ClinicalTrials.gov

17. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    5 in total

    Run by

    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

18. PET/MR for Characterization of Renal Masses (RMs)

    The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatmen…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Locations

    2 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT06076538 on ClinicalTrials.gov

19. A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

    Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib.…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology ( Site 0133), Anchorage, Alaska

    Locations

    127 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07227402 on ClinicalTrials.gov

20. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

    The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEO-811 Los Angeles Site, Duarte, California

    Locations

    12 in total

    Run by

    Neomorph, Inc

    See if you can join NCT07300241 on ClinicalTrials.gov

21. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

    This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT07285044 on ClinicalTrials.gov

22. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

23. Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

    This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, Davis, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT06101290 on ClinicalTrials.gov

24. Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

    This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT06265285 on ClinicalTrials.gov

25. Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

    To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Irvine, California

    Locations

    6 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06053658 on ClinicalTrials.gov